Modulation of the neuronal response to N-methyl-D-aspartate by selective sigma2 ligands

Synapse
S Couture, G Debonnel

Abstract

It has now been accepted for several years that sigma (sigma) receptors exist in, at least, two distinct entities denoted sigma1 and sigma2. Previous electrophysiological studies from our laboratory have demonstrated that several selective sigma1 ligands potentiate the neuronal response to NMDA. The nonselective sigma1/sigma2 ligand DTG also potentiates the NMDA response. However, when DTG is administered at doses between 3 and 40 microg/kg, the increase of NMDA-induced activation turns to an epileptoid activity. Until recently, the physiological role of sigma2 receptors had been less studied due to the lack of selective sigma2 ligands. The goal of the present electrophysiological studies was to assess the effect of the intravenous administration of new selective sigma2 ligands on the neuronal response to NMDA in the CA3 region of the rat dorsal hippocampus. Lu 28-179 and BD 1008 potentiated dose-dependently the NMDA response and generated bell-shaped dose-response curves. These ligands failed to generate any epileptoid activity on their own but the subsequent administration of a low dose of a sigma1 agonist (JO-1784) induced an epileptoid activity. Interestingly, the potentiations of the NMDA response induced by Lu 28-179 or B...Continue Reading

References

Mar 1, 1992·Trends in Pharmacological Sciences·R QuirionD P Taylor
Apr 25, 1990·European Journal of Pharmacology·F P MonnetC De Montigny
Jun 21, 1990·European Journal of Pharmacology·F P MonnetC de Montigny
Dec 19, 1989·European Journal of Pharmacology·F J RomanJ L Junien
Oct 1, 1986·Physiology & Behavior·J P Kroon, A L Riley
Jun 6, 1995·European Journal of Pharmacology·W D BowenA E Jacobson
Mar 1, 1995·Naunyn-Schmiedeberg's Archives of Pharmacology·R BergeronG Debonnel
Nov 1, 1994·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·M YamadaH Miyaji
Aug 24, 1993·European Journal of Pharmacology·R BergeronC De Montigny
May 1, 1961·Journal of Neurophysiology·E R KANDEL, W A SPENCER

❮ Previous
Next ❯

Citations

Sep 14, 1999·British Journal of Pharmacology·R BergeronG Debonnel
Jan 12, 2010·Behavioural Brain Research·Aren van WaardeRudi A Dierckx
Jun 10, 2015·Journal of Receptor and Signal Transduction Research·Colin G Rousseaux, Stephanie F Greene
Feb 9, 2000·Frontiers in Neuroendocrinology·N A Compagnone, S H Mellon
Mar 8, 2005·Journal of Pharmacological Sciences·Jordanna E Bermack, Guy Debonnel
Aug 3, 2005·Psychopharmacology·Cruz M CendánJosé M Baeyens

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here